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Abstract
Although internal medicine wards (IMWs) represent a significant
reservoir of patients with candidemia, few investigators have
specifically addressed the epidemiological aspects of candidaemia
in this population. Of all patients hospitalized during the study
period with candidaemia, 133/348 (38%) were admitted to
IMWs. Variables associated with IMWs included: antibiotic
therapy prior to hospitalization, urinary or central venous
catheter, parenteral nutrition, tumour and age >75 years.
Overall, 30-day mortality in IMWs was significantly higher than
that in other wards (51.1% vs. 38.2%, p <0.02).Multiple logistic
regression analysis identified the administration of antifungal
treatment 48 h after having the first positive BC as an
independent determinant of hospital mortality.Patients with
candidaemia in IMWs account for a substantial proportion of
patients with candidaemia and have higher mortality compared
with patients in other wards.
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The incidence of candidaemia in tertiary care hospitals
worldwide has increased substantially over recent decades
[1–3] due to the increasing complexity of surgical procedures,
the existence of patient populations at higher risk of infection,
and the changes in patient demographic characteristics.
Candidaemia is associated with higher rates of inadequate
initial antimicrobial treatment compared with bacterial blood-
stream infections and carries high mortality rates [4,5].
Although the importance of early treatment of candidaemia
has been clearly demonstrated by some investigators [6,7], a
recent study did not show survival benefit when early
appropriate antifungal therapy was started [8].
The epidemiology of candidaemia has been studied extensively
worldwide. Data are available from large series of laboratory-
based and population-based surveillance studies, aswell as studies
focusing on specific patient populations, such as neonates and
cancer, surgical and critically ill patients [2,9–11]. Although
internal medicine wards (IMWs) represent a significant reservoir
of patientswith candidaemia,with a prevalence ranging from24 to
57%, few investigators have specifically addressed the epidemi-
ological aspects of candidaemia in this population [12,13]. As
bloodstream infections (BSIs) could have different clinical
presentation and outcomes in IMW patients when compared
with those in other wards, we hypothesized that candidaemia in
IMWs may present peculiar aspects in patient care.
To characterize these putative peculiarities, we evaluated
the data collected from a laboratory-based surveillance
database of patients with candidaemia [2]. Our study specif-
ically compared the clinical and epidemiological aspects of
candidaemia in IMWs versus other wards.
A retrospective analysis of episodes of candidaemia in adults
collected from the electronic database of a 1500-bed tertiary
care hospital in Italy was performed over a 3-year period.
Demographics, underlying diseases, co-morbidities, Candida
species distribution, time to initiate antifungal treatment and
outcome were compared among the patients admitted to the
IMW and other hospital wards (i.e. hemato-oncology, intensive
care unit, general surgery).
A case of candidaemia was defined as a patient with at least
one blood culture positive for Candida species.
Isolates were detected from blood cultures using the BAC-
TEC 860 system (Becton Dickinson, Inc., Sparks, MD, USA). The
species were identified using the API-32C system (bioMerieux
Vitek, Inc., St. Louis, MI, USA). Antifungal susceptibility testing of
isolates of Candida spp. was performed by the reference broth
microdilution method described by the Clinical and Laboratory
Standards Institute [14].
Appropriate antifungal treatment was considered when the
treatment was started within 48 h from the first blood culture
performed [8].
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Survival or crudemortalitywas registered as outcome up until
30 days from the occurrence of the episode of candidaemia.
The study was approved by the local institutional review
board (Comitato Etico, Azienda Ospedaliera Universitaria San
Martino) and written patient consent was not required
because of the observational nature of this study.
All patients diagnosed with candidaemia between January
2008 and December 2010 were included in the study. Of all
patients hospitalized during the study period with a diagnosis of
candidemia, 133/348 (38%) were admitted to an IMW.Mean age
and standard deviation were 73.2  14.8 years; 81 (60%) were
male and 52 (30%) female. As summarized in Table 1, compared
with IMWs the other hospital wards had a significantly lower
mean age (73.2  14.8 vs. 64.1  15.3 years, respectively,
p <0.001) and Apache II score (21.2  8.9 vs. 17.1  12.2,
respectively, p <0.005), and a higher percentage of women was
registered (102/208, 49%).
Demographics, risk factors associated with development
of hospital-acquired infections (HAIs) and Candida species
distribution were compared between IMWs and other hospital
wards (Table 1). The overall number of C. albicans (CA) and
C. non albicans (CNA) was similar and equally distributed
between IMWs and other wards, with CA accounting for
47.4% and 50.5%, respectively. Higher percentages of C. kruzei
were reported in other wards compared with IMWs. C. trop-
icalis is more frequent in IMWs.
Variables that were associated with the internal medicine
setting compared with other wards included the receipt of
antibiotic therapy within 1 month prior to hospitalization,
placement of a urinary catheter or central venous catheter,
parenteral nutrition, the presence of a solid tumuor and age
above 75 years (Table 1).
Overall, 30-day mortality of IMW patients was significantly
higher than that of patients in other wards (51.1% vs. 38.2%,
respectively; p <0.02).
To evaluate the factors having an impact on mortality
among patients with candidaemia in IMWs, the timing of the
start of antifungal therapy was recorded and defined as
described in the previous section. Data were available from
97% of the patients in IMWs (133/137) and other wards (202/
208). From the time that the first positive blood culture was
drawn, ten patients (7%) received appropriate antifungal
treatment within 48 h, 15 (11%) patients received antifungal
treatment between 48 and 72 h, and 91 (69%) patients
received antifungal treatment after 72 h. Of note, 17 (13%)
patients did not receive any antifungal treatment (Table 2,
Fig. 1). Overall, while the mortality was around 20% among
patients receiving a prompt antifungal therapy, administration
of antifungals beyond 48–72 h in IMWs and other hospital
wards resulted in mortality rates of 52% and 41%, respectively.
When no antifungal treatment was administered, 30-day crude
mortality reported in IMWs and other wards reached 70.6%
and 75%, respectively.
Mortality rates according to the timing of antifungal
administration in IMWs and other hospital wards are repre-
sented in Table 2. An adequate antifungal administration within
48 h from the first positive blood culture was achieved in only
7.3% of patients treated in IMWs and in 25.5% of patients
treated in other wards (p <0.001). When overall crude
mortality was observed between IMWs and other hospital
wards, a significantly higher mortality was reported in patients
hospitalized in IMWs who received delayed (>96 h) or no
antifungal treatment compared with those in other hospital
wards (Table 2).
TABLE 1. Factors associated with hospitalization in IMWs compared with other wards
Variable IMW (n = 137)
Others (n = 208)
p valueaSurgery (n = 111) Haemato-oncology (n = 29) ICU (n = 68) Total
Mean age (SD) 73.2 (14.8) 62 (14.1) 66.4 (14.2) 57.2 (13.7) 64.1 (15.3) <0.001
Male sex (%) 81 (59.1) 54 (49) 16 (55) 36 (53) 106 (51) 0.152
Apache II score (SD) 21.2 (8.9) 12.4 (7.1) 16.5 (7.7) 21.4 (10.4) 17.1 (12.2) 0.008
C. albicans (%) 65 (47.4) 55 (49.6) 10 (34.5) 40 (58.8) 105 (50.5) 0.581
C. non albicans (%) 72 (52.6) 56 (50.4) 19 (65.5) 28 (41.2) 103 (49.5) 0.581
C. parapsilosis 40 (29.2) 34 (27) 4 (27) 20 (29) 58 (27.9) 0.791
C. tropicalis 16 (11.7) 2 (1.8) 4 (13.8) 1 (1.5) 7 (3.4) 0.002
C. glabrata 9 (6.6) 15 (13.5) 4 (13.8) 5 (7.3) 24 (11.5) 0.125
C. krusei 0 0 7 (24.1) 0 7 (3.4) 0.030
Other 7 (5.1) 5 (4.5) 0 2 (2.9) 7 (3.4) 0.422
Age > 75 years (%) 71 (51.8) 36 (32.4) 5 (17.2) 18 (26.5) 59 (28.4) <0.001
Urinary catheter (%) 97 (70.8) 12 (10.8) 9 (31) 61 (89.7) 82 (39.4) <0.001
Renal failure (%) 45 (32.8) 19 (17.2) 11 (38) 27 (39.7) 57 (27.4) 0.281
Antibiotic therapy within 1 month (%) 100 (73) 54 (48.7) 16 (55.2) 37 (54.4) 107 (51.4) <0.01
Solid tumour (%) 71 (51.8) 22 (19.8) 7 (24.1) 13 (19.1) 42 (20.2) <0.001
Days of hospital stay (range) 28.4 (13–96) 12.4 (9–38) 32.1 (19–115) 15.8 (14–67) 19.2 (12–115) 0.113
Parenteral nutrition (%) 108 (78.8) 52 (46.9) 8 (27.6) 33 (48.5) 93 (44.7) <0.005
Central venous catheter (%) 111 (81) 31 (27.9) 16 (55.2) 64 (94.1) 117 (56.3) <0.01
Diabetes (%) 39 (28.5) 38 (34.2) 5 (17) 9 (13) 52 (25) 0.475
30-day crude mortality (%) 69 (50.4) 33 (29.7) 13 (44.8) 31 (45.6) 75 (36.1) 0.008
aP value of comparison between IMWs and other wards.
Bold values represent significant differences between IMW and other wards.
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Multiple logistic regression analysis identified the adminis-
tration of antifungal treatment 48 h after having the first
positive BC as an independent determinant of hospital
mortality (OR = 12.36, 95% CI 1.54–99.58, p 0.0017).
The epidemiology, risk factors and mortality for candida-
emia in IMWs at a tertiary care hospital in Italy has been
evaluated in this study. More than one-third of the candidaemic
patients were admitted in this setting, where usually elderly
patients with a long hospital stay and multiple risk factors for
invasive candidiasis are hospitalized. Infections in elderly
patients are currently a major public health concern, gaining
increasing relevance because of the expansion of this popu-
lation worldwide [15]. In addition, the population of immuno-
compromised patients in this age group has increased, with an
expanded population of elderly patients undergoing invasive
procedures and organ transplantation and receiving aggressive
cancer chemotherapies. Although the underlying conditions
that are typically associated with candidaemia are frequent in
the IMW population, the characteristics of candidemia in
IMWs have not been extensively studied.
In the present study, elderly patients above 75 years old
represented 51.8% of the candidaemia episodes in IMWs,
where the mean age was higher than in other wards (73.2%
vs. 64.1%, p 0.008). Similar results have been recently
published in a Brazilian study on candidaemia [13]. Patients in
IMWs had a higher prevalence of solid tumour, central
venous and urinary catheters, previous antibiotic treatment
rates and parenteral nutrition. These represent well-known
risk factors reported in several studies [2,3,13]. Thus, the
IMW population represents a suitable target for Candida spp.,
with favourable conditions for the infection to develop. The
species distribution in the present series is typical of the
local epidemiology [2], characterized by a predominance of
C. albicans, C. parapsilosis and C. tropicalis, and low proportion
of C. glabrata. In contrast, candidaemia due to C. tropicalis
was significantly more frequent in the IMWs. As confirmed
by the present study, an association between C. tropicalis
candidaemia and elderly patients has been reported in studies
conducted in Brazil, Saudi Arabia, Taiwan and Singapore
[13,16–19].
A major finding of the present study is the high mortality rate
for candidaemia in patients admitted to IMWs compared with
other wards (50.4% vs. 36.1%, p 0.008). Several factors may have
had an impact on the outcome (i.e. the high APACHE II score,
the age of the patients and the presence of multiple co-
morbidities). Therefore, it is reasonable to assume that these
factors made a major contribution towards poor outcomes in
IMWs compared with other wards. Thus, factors potentially
prone to intervention should be explored in future studies.
Our study confirmed that a delay in initial empirical
treatment for fungal BSI of more than 48 h after a positive
blood culture is very common and is associated with a greater
risk of hospital mortality in IMWs compared with appropriate
treatment within 48 h (Fig. 1). Of note, in 21% of the
candidaemic episodes, the antifungal therapy was started after
96 h or was never started. Our results confirm previous
experiences, in which a relationship between delaying the
initiation of antifungal therapy and mortality was demonstrated
[6,7]. This study has some important limitations, the most
significant being its retrospective nature. While all data had
been collected prospectively, some variables could not be
explored because of missing data. These included clinical
TABLE 2. Correlation between
30-day crude mortality and timing to
antifungal administration in IMWs
and other hospital wards
Variable
Treatment (%) Mortality (%)a
Timing IMW (n = 133) Others (n = 202) p value IMW (n = 133) Others (n = 202)
<48 h 10 (7.5) 53 (26.2) <0.001 2/10 (20) 11/53 (21)
48–72 h 15 (11.3) 77 (38.1) 0.001 5/15 (33.3) 21/77 (27)
72–96 h 38 (28.6) 39 (19.3) 0.049 20/38 (53) 22/39 (56)
>96 h 53 (39.8) 25 (12.3) <0.001 30/53 (57) 15/25 (60)
No therapy 17 (12.8) 8 (3.9) 0.003 12/17 (71) 6/8 (75)








< 48 h 48–72 h 72– 96 h > 96 h no Therapy 
FIG. 1. Relationship between hospital mortality and the timing of
antifungal treatment. The timing of antifungal therapy was determined
to be from the time when the first blood sample for culture that was
positive for fungi was drawn to the time when antifungal treatment was
first administered to the patient. *p 0.03 between <48 h and >48 h or
no therapy.
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manifestations of infection (severe sepsis and/or septic shock),
the dosesof corticosteroids and the timingof some interventions,
such as CVC removal. Second, our study was performed at a
single site and the results may not be applicable to other settings.
In conclusion, patients with candidaemia in IMWs account
for a substantial proportion of patients with candidaemia and
have higher mortality compared with patients in other wards.
Considering the high mortality rate in this population,
measures with the potential to improve their outcome should
be explored. These include an early start to antifungal
treatment (prophylactic, empirical or preemptive), as well as
the use of better methods to identify patients at risk of fungal
infections in this setting.
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